$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti

$rmti Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000162828020007479 Filed on May 11, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$15.86M	$15.56M
YoY Change	1.91%	4.08%
Cost Of Revenue	$14.74M	$14.55M
YoY Change	1.34%	-7.15%
Gross Profit	$1.113M	$1.010M
YoY Change	10.16%	-240.33%
Gross Profit Margin	7.02%	6.49%
Selling, General & Admin	$7.346M	$9.323M
YoY Change	-21.2%	179.97%
% of Gross Profit	660.02%	922.7%
Research & Development	$1.822M	$497.3K
YoY Change	266.4%	-70.22%
% of Gross Profit	163.7%	49.22%
Depreciation & Amortization	$209.0K	$187.5K
YoY Change	11.45%	44.25%
% of Gross Profit	18.78%	18.56%
Operating Expenses	$9.168M	$9.820M
YoY Change	-6.64%	96.4%
Operating Profit	-$8.055M	-$8.810M
YoY Change	-8.57%	54.02%
Interest Expense	$102.0K	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	$71.00K	$131.4K
YoY Change	-45.97%
Pretax Income	-$7.980M	-$8.680M
YoY Change	-8.06%	56.4%
Income Tax
% Of Pretax Income
Net Earnings	-$7.984M	-$8.679M
YoY Change	-8.01%	56.38%
Net Earnings / Revenue	-50.35%	-55.78%
Basic Earnings Per Share	-$0.12
Diluted Earnings Per Share	-$0.12	-$152.0K
COMMON SHARES
Basic Shares Outstanding	67.52M shares
Diluted Shares Outstanding	67.52M shares

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$48.90M	$27.80M
YoY Change	75.9%	-1.07%
Cash & Equivalents	$37.40M	$20.92M
Short-Term Investments	$11.50M	$6.880M
Other Short-Term Assets	$1.760M	$1.680M
YoY Change	4.76%	4.35%
Inventory	$4.293M	$4.000M
Prepaid Expenses
Receivables	$4.587M	$6.710M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$59.49M	$40.19M
YoY Change	48.03%	-2.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.430M	$5.580M
YoY Change	-56.45%	117.12%
Goodwill	$920.7K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$560.6K	$2.060M
YoY Change	-72.79%	-68.31%
Total Long-Term Assets	$7.332M	$8.560M
YoY Change	-14.34%	-14.4%
TOTAL ASSETS
Total Short-Term Assets	$59.49M	$40.19M
Total Long-Term Assets	$7.332M	$8.560M
Total Assets	$66.83M	$48.75M
YoY Change	37.08%	-4.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.123M	$4.520M
YoY Change	-30.9%	12.72%
Accrued Expenses	$6.160M	$7.950M
YoY Change	-22.52%	149.22%
Deferred Revenue	$2.179M
YoY Change
Short-Term Debt	$190.0K	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.36M	$15.73M
YoY Change	-15.08%	61.83%
LONG-TERM LIABILITIES
Long-Term Debt	$20.68M	$0.00
YoY Change
Other Long-Term Liabilities	$11.01M	$12.85M
YoY Change	-14.32%	-7.29%
Total Long-Term Liabilities	$20.68M	$12.85M
YoY Change	60.96%	-7.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.36M	$15.73M
Total Long-Term Liabilities	$20.68M	$12.85M
Total Liabilities	$45.05M	$28.58M
YoY Change	57.63%	21.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$314.5M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$21.77M	$20.16M
YoY Change
Total Liabilities & Shareholders Equity	$66.83M	$48.75M
YoY Change	37.08%	-4.8%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$7.984M	-$8.679M
YoY Change	-8.01%	56.38%
Depreciation, Depletion And Amortization	$209.0K	$187.5K
YoY Change	11.45%	44.25%
Cash From Operating Activities	-$6.538M	-$5.424M
YoY Change	20.55%	17.65%
INVESTING ACTIVITIES
Capital Expenditures	-$200.0K	-$120.0K
YoY Change	66.67%	-25.0%
Acquisitions
YoY Change
Other Investing Activities	$2.790M	$3.700M
YoY Change	-24.59%	-1100.0%
Cash From Investing Activities	$2.586M	$3.577M
YoY Change	-27.7%	-787.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$8.000M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$29.56M	$52.47K
YoY Change	56230.16%
NET CHANGE
Cash From Operating Activities	-$6.538M	-$5.424M
Cash From Investing Activities	$2.586M	$3.577M
Cash From Financing Activities	$29.56M	$52.47K
Net Change In Cash	$25.61M	-$1.794M
YoY Change	-1526.89%	-65.02%
FREE CASH FLOW
Cash From Operating Activities	-$6.538M	-$5.424M
Capital Expenditures	-$200.0K	-$120.0K
Free Cash Flow	-$6.338M	-$5.304M
YoY Change	19.5%	19.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	143913	USD
CY2019Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	8812954	USD
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001041024
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	69069078	shares
CY2018Q4	rmti	Number Of Additional Agreements NumberOfAdditionalAgreements	3	agreement
CY2020Q1	rmti	Number Of Distribution And License Agreements NumberOfDistributionAndLicenseAgreements	3	agreement
CY2019Q1	rmti	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	478442	USD
CY2020Q1	rmti	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	390517	USD
CY2019Q1	rmti	Repurchase Of Common Shares To Pay Employee Withholding Taxes RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes	95429	USD
CY2020Q1	rmti	Repurchase Of Common Shares To Pay Employee Withholding Taxes RepurchaseOfCommonSharesToPayEmployeeWithholdingTaxes	0	USD
CY2019Q4	rmti	Research And Development Related Liabilities Current ResearchAndDevelopmentRelatedLiabilitiesCurrent	283407	USD
CY2020Q1	rmti	Research And Development Related Liabilities Current ResearchAndDevelopmentRelatedLiabilitiesCurrent	227152	USD
CY2020Q1	rmti	Saleof Stock Remaining Sales Amount SaleofStockRemainingSalesAmount	34616921	USD
CY2020Q1	rmti	Self Insurance Retention Amount SelfInsuranceRetentionAmount	1000000	USD
CY2020Q1	rmti	Working Capital Net WorkingCapitalNet	46100000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3018424	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3123181	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4202725	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4586748	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4517732	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6160047	USD
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q1	rmti	Average Payment Term Of Customers AveragePaymentTermOfCustomers	P30D
CY2020Q1	rmti	Average Payment Term Of Distributors AveragePaymentTermOfDistributors	P45D
CY2019Q1	rmti	Contract With Customer Asset Credit Loss Expense Recognized ContractWithCustomerAssetCreditLossExpenseRecognized	0	USD
CY2020Q1	rmti	Contract With Customer Asset Credit Loss Expense Recognized ContractWithCustomerAssetCreditLossExpenseRecognized	0	USD
CY2019Q4	rmti	Current And Non Current Inventory CurrentAndNonCurrentInventory	4087906	USD
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	rmti	Current And Non Current Inventory CurrentAndNonCurrentInventory	4915768	USD
CY2019Q4	rmti	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	0	USD
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	ROCKWELL MEDICAL, INC.
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	rmti	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent	59665	USD
CY2019Q1	rmti	Delivery Of Common Stock Restricted Stock Units DeliveryOfCommonStockRestrictedStockUnits	273830	USD
CY2020Q1	rmti	Delivery Of Common Stock Restricted Stock Units DeliveryOfCommonStockRestrictedStockUnits	0	USD
CY2019Q1	rmti	Increase Decrease In Operating Lease Liabilites IncreaseDecreaseInOperatingLeaseLiabilites	-467440	USD
CY2020Q1	rmti	Increase Decrease In Operating Lease Liabilites IncreaseDecreaseInOperatingLeaseLiabilites	-338668	USD
CY2019Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	61164	USD
CY2020Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	129936	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	181597	USD
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	339606	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5864968	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6042449	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	51980	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	934846	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	336216422	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	50881	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	326777250	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12076000	USD
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	11630000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1517302	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	500736	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1517302	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	934847	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	15262	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9898322	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13048405	shares
CY2019Q4	us-gaap	Assets Assets	44316452	USD
CY2020Q1	us-gaap	Assets Assets	66825809	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	36873837	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	59493604	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13321	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22356	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1306	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10789	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	14250176	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11456285	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11500000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11794526	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37399801	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37400000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22713980	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20919518	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11794526	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37399801	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1794462	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	25605275	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	170000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	65378890	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	69049102	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	65378890	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	69049102	shares
CY2019Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	6538	USD
CY2020Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	6905	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8685600	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7984837	USD
CY2019Q1	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	USD
CY2020Q1	us-gaap	Contract With Customer Asset Credit Loss Expense ContractWithCustomerAssetCreditLossExpense	0	USD
CY2019Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2233640	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2179383	USD
CY2019Q3	us-gaap	Debt Instrument Term DebtInstrumentTerm	P10M
CY2019Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	187849	USD
CY2020Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	148523	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2020Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	956782	USD
CY2020Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	14238161	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	11385053	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	13888	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9842762	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14549047	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14743613	USD
CY2019Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1900000	USD
CY2019Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0465
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9450983	USD
CY2019Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	55100	USD
CY2020Q1	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	146831	USD
CY2020Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	1929	USD
CY2019Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	187527	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	209367	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1018196	USD
CY2020Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1920577	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	92	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-5611	USD
CY2019Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	13888	USD
CY2020Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1929	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6220499	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5273433	USD
CY2019Q4	us-gaap	Goodwill Goodwill	920745	USD
CY2020Q1	us-gaap	Goodwill Goodwill	920745	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	1010392	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	1112926	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	30154	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	104757	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-268104	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	384024	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-563217	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-446036	USD
CY2019Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-249999	USD
CY2020Q1	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-47000	USD
CY2019Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	-371217	USD
CY2020Q1	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	0	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-162208	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	827861	USD
CY2019Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-1074384	USD
CY2020Q1	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	108366	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1319375	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	737937	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-203982	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1092529	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	101951	USD
CY2019Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	80908	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1432290	USD
CY2020Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1873886	USD
CY2019Q1	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	11000	USD
CY2020Q1	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	0	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	3646906	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	4292768	USD
CY2019Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	441000	USD
CY2020Q1	us-gaap	Inventory Noncurrent InventoryNoncurrent	623000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2471234	USD
CY2020Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2750185	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	184382	USD
CY2020Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	291697	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	117526	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	171077	USD
CY2019Q1	us-gaap	Lease Cost LeaseCost	629003	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	636268	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3168677	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	97423	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	234327	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	591925	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1054873	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1190129	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	257580	USD
CY2019Q4	us-gaap	Liabilities Liabilities	23996949	USD
CY2020Q1	us-gaap	Liabilities Liabilities	45051604	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44316452	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	66825809	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12373561	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13357168	USD
CY2019Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	104000	USD
CY2020Q1	us-gaap	Litigation Reserve Current LitigationReserveCurrent	57000	USD
CY2019	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	400000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20683704	USD
CY2020Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	3000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	52471	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29557349	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3576739	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2586356	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5423672	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6500000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.068
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.068
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1351348	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1780626	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1559749	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	523965	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	444693	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3212530	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2797759	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2800000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1493394	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6538430	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-8678347	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-7983738	USD
CY2019Q4	us-gaap	Notes Payable NotesPayable	763422	USD
CY2020Q1	us-gaap	Notes Payable NotesPayable	200000	USD
CY2020Q1	us-gaap	Notes Payable NotesPayable	190855	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8809761	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8054793	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	534967	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	442828	USD
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	624811	USD
CY2020Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	632111	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2911097	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2900000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M6D
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y7M6D
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2973368	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3542776	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	434935	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	560588	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7161	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-6710	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-92	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	5611	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-7161	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-6710	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	131414	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	71055	USD
CY2019Q4	us-gaap	Other Receivables OtherReceivables	4203000	USD
CY2020Q1	us-gaap	Other Receivables OtherReceivables	4587000	USD
CY2019Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	374043	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	309479	USD
CY2020Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	8871583	USD
CY2019Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	250000	USD
CY2020Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	USD
CY2019Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	121826	USD
CY2020Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	202753	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2020Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2979504	USD
CY2020Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1758002	USD
CY2020Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	21200000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8000000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5383079	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8147871	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	22500000	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	12761519	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	11660692	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	147900	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8298373	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8472562	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2433405	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2430113	USD
CY2018	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	1100000	USD
CY2019Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2020Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	572566	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	497276	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1821488	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-306516265	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-314500003	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-314500000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	15559000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	15559439	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	15857000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	15856539	USD
CY2020Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	11600000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3484234	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	3670212	shares
CY2019Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3102378	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2072798	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1517302	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	934846	USD
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.92
CY2019Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4192	USD
CY2020Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	4157	USD
CY2019Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020Q1	us-gaap	Stock Issued1 StockIssued1	500736	USD
CY2019	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1840443	shares
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8003957	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-95429	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	147900	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	27276874	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	20161047	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20319503	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	21774205	USD
CY2019Q1	us-gaap	Variable Lease Cost VariableLeaseCost	89844	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	189283	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	57098947	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	67518240	shares
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-20-007479-index-headers.html	Edgar Link	pending
0001628280-20-007479-index.html	Edgar Link	pending
0001628280-20-007479.txt	Edgar Link	pending
0001628280-20-007479-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rmti-20200331.xml	Edgar Link	completed
rmti-20200331.xsd	Edgar Link	pending
rmti-20200331x10q.htm	Edgar Link	pending
rmti-20200331x10qex101.htm	Edgar Link	pending
rmti-20200331x10qex311.htm	Edgar Link	pending
rmti-20200331x10qex312.htm	Edgar Link	pending
rmti-20200331_cal.xml	Edgar Link	unprocessable
rmti-20200331_def.xml	Edgar Link	unprocessable
rmti-20200331_lab.xml	Edgar Link	unprocessable
rmti-20200331_pre.xml	Edgar Link	unprocessable
rmti-20200631x10qex321.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti

2020 Q1 Form 10-Q Financial Statement

#000162828020007479 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTI ROCKWELL MEDICAL, INC. Stock $rmti

2020 Q1 Form 10-Q Financial Statement

#000162828020007479 Filed on May 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMTI
ROCKWELL MEDICAL, INC. Stock $rmti